BioNxt Solutions Inc.
15.8.2024 22:04:41 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group.
Further to the Master Service Agreement and Cladribine Statement of Work signed by BioNxt and Gen-Plus announced on July 9, 2024, and July 17, 2024, respectively, the LOI recognizes a number of important areas of potential cooperation between the parties, including but not limited to intellectual property and prototype development for new pharmaceutical products, clinical trial planning and batch manufacturing, laboratory, equipment, and office collaboration, business development, and thin film commercial manufacturing. The Company will provide further details on specific cooperation programs as they progress.
Gen-Plus, a part of Conscio Group, has a head office in Munich, Germany, and through the Conscio Group operates within an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New Pharma AI Findings Reveal the Real Barrier to Scale: Execution, Not Innovation15.6.2026 12:00:00 CEST | Press release
GENEVA, SWITZERLAND AND WARSAW, POLAND / ACCESS Newswire / June 15, 2026 / Pharma companies are no longer struggling to identify AI opportunities - they are struggling to scale them. New findings from Lingaro, based on research with 150 senior pharma and life sciences leaders, show that AI has strong strategic visibility across the sector, yet most organizations lack the foundations needed to turn early momentum into consistent business impact. Nearly 60% of respondents say their AI strategy lacks clear ownership, highlighting a gap between leadership ambition and operational accountability. Without defined business ownership and success metrics, many companies remain stuck between experimentation and scaled delivery. Data is another barrier. According to the research, 67.3% of pharma leaders report fragmented or only partly reliable data. In a sector where commercial, medical, regulatory, and patient data often sit in disconnected systems, poor data quality can delay decisions, reduce
Litum Brings High-Precision Location Visibility to Zone 1 and Zone 2 Hazardous Environments15.6.2026 09:00:00 CEST | Press release
Combining ATEX Zone 1 and Zone 2 suitability with high-precision location capability, the ATEX Gateway and ATEX Dualis Tag set a new benchmark for intrinsically safe RTLS in hazardous industrial environments BOSTON, MA / ACCESS Newswire / June 15, 2026 / Litum, a global leader in real-time location systems, today announced the ATEX Family: a purpose-built hardware suite comprising the ATEX Gateway and ATEX Dualis Tag. Compliant with both Zone 1 and Zone 2 hazardous areas, the ATEX Family is designed to deliver sub-meter location accuracy and better visibility in environments where standard connected devices cannot be safely deployed. The launch marks a significant step forward for industrial organizations that need to track critical assets, equipment, tools, materials, and people in environments where explosive gases, vapors, or combustible dust may be present. By combining intrinsically safe design with Ultra-Wideband (UWB) and Bluetooth Low Energy (BLE) location capability, Litum ena
GA-ASI and INTEC Group Sign MOU at ILA Berlin11.6.2026 17:00:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / June 11, 2026 / Today at the ILA Berlin Air Show, General Atomics Aeronautical Systems, Inc. (GA-ASI) and the INTEC Group signed a Memorandum of Understanding (MoU) for INTEC to support the architecture and integration of mission systems, entry into service and logistic support services for GA-ASI's Gambit Series of Collaborative Combat Aircraft (CCA). The work is intended to provide sovereign capabilities to meet the growing interest in CCA in Germany. The MoU was signed by GA-ASI CEO Linden Blue and INTEC Group CEO Christoph Otten. GA-ASI's flight-proven Gambit CCA provides a common platform for air-to-air, air-to-ground and electronic warfare missions. Gambit is an uncrewed combat jet optimized for attack roles such as electronic warfare, Suppression of Enemy Air Defenses (SEAD), Destruction of Enemy Air Defenses (DEAD) and stand-off precision strike, making it a versatile option for evolving security needs. GA-ASI is currently flight testing the YFQ-4
U.S. Polo Assn. Palm Beaches Marathon Celebrates America's 250th, Adds $17,000 in Prize Money as it Returns December 12-13, 202611.6.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / June 11, 2026 / The 2026 U.S. Polo Assn. Palm Beaches Marathon, a celebration of America's 250th, will introduce prize money for its top Marathon runners for the first time when the race returns to the streets of West Palm Beach on December 12-13, 2026, a move that will attract elite runners worldwide and elevate the status of Palm Beach County's most treasured road test. The introduction of $17,000 in prize money is the next strategic step for elevating this racing event that has experienced record growth in recent years. The men's and women's winners of the Marathon race will each receive $5,000, second-place finishers will receive $2,500, and third place will be worth $1,000. The winners' share of the purse is the largest in the state of Florida. In celebration of America's 250th, the 2026 U.S. Polo Assn. Palm Beaches Marathon Logo has been re-designed in stunning brushstrokes of red, white and blue to accompany the brand's iconic double horse
Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 202610.6.2026 14:30:00 CEST | Press release
LADOS connects Ondas' systems, including sensors, effectors, autonomous platforms, and command units, into one immediate operational core for integrated missions and serves as a critical systems-of-systems command-and-control layer LADOS is part of Ondas' multi-domain software architecture that includes SkyWeaver, a Palantir-powered Agentic AI layer for Multi-Domain Mission Autonomy and long-range ISR-to-assault applications The system will be officially launched at Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions WEST PALM BEACH, FL / ACCESS Newswire / June 10, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous drone and advanced defense technologies, today announced that it will officially launch LADOS - a Layered Autonomous Defense Operational C2 System, during Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions. LADOS serves as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom